◆英語タイトル:Navidea Biopharmaceuticals Inc (NAVB) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011047
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月21日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Navidea Biopharmaceuticals Inc (Navidea) is a precision medicine company that focuses on the development and commercialization of radiopharmaceutical agents and precision diagnostics. Its key product, Lymphoseek (technetium Tc 99m tilmanocept) injection, is a radiopharmaceutical agent used in intra-operative lymphatic mapping (ILM), external lymph node imaging (lymphoscintigraphy) and sentinel lymph node biopsy. The company’s products in pipeline includes lifecycle management of Lymphoseek; and NAV4694, a fluorine-18 PET (positron emission tomography) imaging agent, is being developed for the diagnosis of cognitive impairment and dementia, including Alzhemier’s disease. Navidea by utilizing its Manocept platform develops multiple precision-targeted products to identify pathways of undetected disease and provide better diagnostic accuracy, clinical decision-making and effective treatment. The company has presence in the US, Israel and the UK. Navidea is headquartered in Dublin, Ohio, the US.
Navidea Biopharmaceuticals Inc (NAVB) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Navidea Biopharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Navidea Biopharmaceuticals Inc, Medical Equipment, Deal Details 10
Partnerships 10
Sayre Therapeutics Enters into Licensing Agreement with Navidea Biopharma 10
Naviscan PET Systems Enters Into Licensing Agreement With Neoprobe 11
Cerveau to Enter into Licensing Agreement with Navidea Biopharma 12
Equity Offering 13
Navidea Biopharma Plans to Raise up to USD100 in Public Offering of Shares 13
Navidea Biopharma Completes Private Placement Of Units For US$30 Million 14
Navidea Biopharma Completes Public Offering Of Common Stock For US$5 Million 16
Navidea Biopharma Completes Private Placement Of Shares For US$5 Million 17
Navidea Biopharma Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 19
Debt Offering 20
Neoprobe Completes Private Placement Of Convertible Secured Note For US$7 Million 20
Asset Transactions 21
Neoprobe Completes Sale Of Gamma Detection Device Business To Devicor Medical Products 21
Navidea Biopharmaceuticals Inc – Key Competitors 23
Navidea Biopharmaceuticals Inc – Key Employees 24
Navidea Biopharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Joint Venture 25
Recent Developments 26
Financial Announcements 26
Nov 08, 2017: Navidea Biopharmaceuticals Reports Third Quarter 2017 Financial Results 26
May 09, 2017: Navidea Biopharmaceuticals Reports First Quarter 2017 Financial Results 28
Mar 29, 2017: Navidea Provides Corporate Update and Reports Full Year 2016 Results 30
Nov 03, 2016: Navidea Reports 2016 Third Quarter Financial Results 33
Aug 04, 2016: Navidea Reports Second Quarter 2016 Financial Results 35
May 17, 2016: Navidea Reports First Quarter 2016 Financial Results 38
Mar 23, 2016: Navidea Announces Fourth Quarter and Full Year 2015 Results 40
Corporate Communications 42
Sep 26, 2016: Navidea Appoints Michael M. Goldberg, M.D. President and Chief Executive Officer 42
Apr 26, 2016: Navidea Appoints Jed Latkin as Interim Chief Operating Officer 43
Product News 44
Nov 01, 2017: Navidea to Present Late-Breaking Abstract at American College of Rheumatology Annual Meeting 44
Apr 25, 2017: Navidea Biopharmaceuticals Invited to Present Data at Two Major Upcoming Conferences 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46
List of Tables
Navidea Biopharmaceuticals Inc, Medical Equipment, Key Facts, 2016 2
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Navidea Biopharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Navidea Biopharmaceuticals Inc, Deals By Market, 2011 to YTD 2017 8
Navidea Biopharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Sayre Therapeutics Enters into Licensing Agreement with Navidea Biopharma 10
Naviscan PET Systems Enters Into Licensing Agreement With Neoprobe 11
Cerveau to Enter into Licensing Agreement with Navidea Biopharma 12
Navidea Biopharma Plans to Raise up to USD100 in Public Offering of Shares 13
Navidea Biopharma Completes Private Placement Of Units For US$30 Million 14
Navidea Biopharma Completes Public Offering Of Common Stock For US$5 Million 16
Navidea Biopharma Completes Private Placement Of Shares For US$5 Million 17
Navidea Biopharma Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 19
Neoprobe Completes Private Placement Of Convertible Secured Note For US$7 Million 20
Neoprobe Completes Sale Of Gamma Detection Device Business To Devicor Medical Products 21
Navidea Biopharmaceuticals Inc, Key Competitors 23
Navidea Biopharmaceuticals Inc, Key Employees 24
Navidea Biopharmaceuticals Inc, Subsidiaries 25
Navidea Biopharmaceuticals Inc, Joint Venture 25